入排依据:The record describes a Phase III RCT with drug intervention in oncology, but the abstract does not explicitly specify a time-to-event efficacy endpoint (like OS, PFS, DFS, etc.) or Kaplan-Meier/HR data. Without this information, the time_to_event criterion cannot be established.
摘要
摘要
In the ASTRUM-007 randomized double-blind phase III study, Song et al.1 showed that the combination of PD-1 inhibitors with first-line fluoropyrimidine and platinum-based chemotherapy improves outcomes in PD-L1-overexpressing esophageal squamous cell carcinomas.
KM 提取结果
0 个 Figure · 0 个 KM 面板